Teva, The Medicines Co. settle suit over blood-thinning drug
PARSIPPANY, N.J. — The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO’s drugs by the end of the decade.
The drug makers announced the settlement in the U.S. District Court for the District of Delaware, whereby Teva can launch a generic version of the injectable anticoagulant drug Angiomax (bivalirudin) in June 2019.
Under the settlement, Teva admits that two patents covering Angiomax are valid, enforceable and would be infringed by Teva’s generic version. The patents are scheduled to expire in July 2028, according to the Food and Drug Administration. MDCO remains in infringement litigation concerning the drug with generic drug makers APP Pharmaceuticals, Hospira, Mylan and Dr. Reddy’s Labs.
In-store marketing gets a new taste at Albertsons
SAN DIEGO — Consumers are busier than ever and are inclined to spend as little time shopping for groceries as possible, so attracting them enough to stop and sample a new product is a challenge. Albertsons is looking to address that issue by teaming with Daymon Interactions, a consumer event marketing company, to develop a new in-house product sampling and event marketing program.
"A Taste of Albertsons" is designed to connect shoppers with vendors through personalized product sampling events, Daymon noted in a press release. The in-store events began Oct. 1, and throughout the first year of operation, A Taste of Albertsons will be featured throughout the United States in Arizona, Texas, New Mexico and Colorado. According to the company, these events will focus on sampling, product launches, holiday promotions, meal-solutions and more. A dedicated sales staff will be on hand to engage customers as well.
“Through this new and dynamic shopping experience, we are able to better serve and bring more value to Albertsons and our vendor partners,” said Daymon Interactions business manager Denise Decker, who will lead the Albertsons account. “Daymon Interactions has a fresh and engaging way to approach in-store events and I think shoppers will respond positively.”
Study: Asthma, COPD markets to see revenue growth, innovation
MOUNTAIN VIEW, Calif. — Growing numbers of Americans with asthma and chronic obstructive pulmonary disease are driving innovation among drug makers, according to a new report by Frost & Sullivan.
More than 40 million Americans were diagnosed with asthma or COPD in 2009, including 25.1 million with asthma and 15.1 million with COPD. Along with the rapid growth in both disease states, revenues have grown as well, with the market earning revenues of $15.4 million in 2009 and on track to earn $17.9 million in 2016. During that same period, seven new drugs are expected to be introduced in the market.
"The number of Americans diagnosed with either asthma or COPD is increasing and expected to reach 43.9 million by 2016," a Frost & Sullivan research analyst said. "This growing number is likely to drive both revenue growth and product innovation in the related therapeutics market."
Still, the introduction of less expensive generics threatens some of the revenue growth, with Merck & Co.’s Singulair (montelukast) and GlaxoSmithKline’s Advair (fluticasone propionate and salmetrol) set to lose patent protection in 2012 and 2016, respectively. But drug companies have continued addressing unmet medical needs of people with asthma and COPD, especially because most drugs for both diseases are inhalants that require devices that are user-friendly and in compliance with Food and Drug Administration requirements.